Your browser is no longer supported. Please, upgrade your browser.
CBAY CymaBay Therapeutics, Inc. monthly Stock Chart
CymaBay Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.94 Insider Own0.40% Shs Outstand68.89M Perf Week-5.24%
Market Cap534.58M Forward P/E- EPS next Y-1.01 Insider Trans0.00% Shs Float65.19M Perf Month-11.40%
Income-64.60M PEG- EPS next Q-0.20 Inst Own84.70% Short Float7.03% Perf Quarter21.60%
Sales- P/S- EPS this Y-22.20% Inst Trans-2.13% Short Ratio3.47 Perf Half Y96.21%
Book/sh2.27 P/B3.42 EPS next Y-40.80% ROA-35.00% Target Price13.00 Perf Year48.57%
Cash/sh2.34 P/C3.31 EPS next 5Y- ROE-37.80% 52W Range1.21 - 9.06 Perf YTD296.43%
Dividend- P/FCF- EPS past 5Y10.40% ROI- 52W High-16.67% Beta1.53
Dividend %- Quick Ratio15.90 Sales past 5Y- Gross Margin- 52W Low523.97% ATR0.50
Employees24 Current Ratio15.90 Sales Q/Q- Oper. Margin- RSI (14)43.12 Volatility6.25% 6.64%
OptionableYes Debt/Eq0.00 EPS Q/Q56.70% Profit Margin- Rel Volume0.63 Prev Close7.77
ShortableYes LT Debt/Eq0.00 EarningsNov 05 AMC Payout- Avg Volume1.32M Price7.55
Recom1.50 SMA20-7.63% SMA50-1.82% SMA20071.78% Volume586,806 Change-2.83%
Aug-04-20Reiterated H.C. Wainwright Buy $9 → $13
Jul-31-20Initiated Piper Sandler Overweight $12
May-26-20Upgrade H.C. Wainwright Neutral → Buy $9
May-12-20Upgrade SVB Leerink Mkt Perform → Outperform $6
May-12-20Upgrade Stifel Hold → Buy $4 → $8
May-12-20Upgrade ROTH Capital Neutral → Buy $15
May-12-20Upgrade Raymond James Mkt Perform → Outperform $7
May-12-20Upgrade Evercore ISI In-line → Outperform $15
Mar-13-20Upgrade Oppenheimer Perform → Outperform $4
Mar-13-20Upgrade Cantor Fitzgerald Neutral → Overweight
Nov-26-19Downgrade ROTH Capital Buy → Neutral $22 → $2
Nov-26-19Downgrade Raymond James Strong Buy → Mkt Perform
Nov-26-19Downgrade H.C. Wainwright Buy → Neutral $16 → $2
Nov-26-19Downgrade Cantor Fitzgerald Overweight → Neutral $20 → $2
Nov-25-19Downgrade SunTrust Buy → Hold
Nov-25-19Downgrade Stifel Buy → Hold
Nov-25-19Downgrade Evercore ISI Outperform → In-line
Jun-25-19Initiated Stifel Buy
Jun-12-19Upgrade Raymond James Outperform → Strong Buy
May-14-19Initiated Citigroup Buy $21
Nov-16-20 04:01PM  
Nov-11-20 08:00AM  
Nov-07-20 02:01AM  
Nov-05-20 04:05PM  
Nov-02-20 08:00AM  
Oct-30-20 04:32PM  
Oct-01-20 08:00AM  
Sep-30-20 09:58AM  
Sep-29-20 11:21AM  
Sep-22-20 07:00AM  
Sep-03-20 04:05PM  
Aug-27-20 08:00AM  
Aug-20-20 08:00AM  
Aug-11-20 03:01AM  
Aug-10-20 04:01PM  
Aug-05-20 03:31PM  
Aug-03-20 04:01PM  
Jul-23-20 08:00AM  
Jul-13-20 03:05AM  
Jul-05-20 09:44AM  
Jun-28-20 07:20PM  
Jun-19-20 08:00AM  
Jun-18-20 08:45AM  
Jun-09-20 05:53PM  
Jun-05-20 05:00PM  
Jun-02-20 10:22AM  
Jun-01-20 08:34AM  
May-26-20 06:12PM  
May-21-20 07:21AM  
May-15-20 08:29AM  
May-13-20 09:37AM  
May-12-20 10:34AM  
May-11-20 04:01PM  
May-04-20 04:43PM  
Apr-02-20 04:01AM  
Mar-20-20 08:30PM  
Mar-13-20 05:29PM  
Mar-12-20 04:01PM  
Mar-11-20 07:00PM  
Mar-10-20 12:15PM  
Mar-09-20 07:51PM  
Mar-06-20 10:49AM  
Mar-05-20 07:00PM  
Mar-04-20 06:09PM  
Mar-03-20 03:12PM  
Mar-02-20 06:50PM  
Feb-28-20 09:52PM  
Feb-05-20 11:52AM  
Jan-29-20 04:15PM  
Jan-15-20 02:25PM  
Jan-10-20 09:21AM  
Dec-31-19 11:48AM  
Dec-17-19 10:31AM  
Dec-10-19 03:36PM  
Dec-09-19 06:09AM  
Dec-08-19 07:09PM  
Nov-29-19 11:24AM  
Nov-27-19 10:09AM  
Nov-26-19 11:07AM  
Nov-25-19 04:20PM  
Nov-22-19 03:22PM  
Nov-14-19 08:00AM  
Nov-05-19 04:10PM  
Nov-04-19 08:00AM  
Nov-03-19 08:11AM  
Oct-28-19 08:00AM  
Oct-18-19 10:23AM  
Oct-14-19 08:00AM  
Oct-01-19 04:05PM  
Sep-30-19 08:00AM  
Sep-28-19 09:35AM  
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.